EWCZ trades 0.3% above Wall Street's consensus target of $5.80.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EWCZ achieves its forward estimates and maintains a stable P/E multiple of 8.5x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, European Wax Center, Inc. (EWCZ) has a Wall Street consensus price target of $5.80, based on estimates from 8 covering analysts. With the stock currently trading at $5.82, this represents a potential downside of -0.3%. The company has a market capitalization of $319M.
Analyst price targets range from a low of $5.80 to a high of $5.80, representing a 0% spread in expectations. The median target of $5.80 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, EWCZ trades at a trailing P/E of 29.1x and forward P/E of 8.5x. Analysts expect EPS to grow +285.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.58, with bear and bull scenarios of $4.14 and $8.66 respectively. Model confidence stands at 39/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
FATFAT Brands Inc. | $3M | $0.16 | — | — | — | — | — |
SKINThe Beauty Health Company | $87M | $0.67 | $1.53 | +130.8% | Hold | — | 14 |
LFSTLifeStance Health Group, Inc. | $3.6B | $9.21 | $9.90 | +10.2% | Buy | 66.0x | 11 |
XPOFXponential Fitness, Inc. | $247M | $6.61 | $7.00 | +2.5% | Buy | 14.8x | 14 |
REGNRegeneron Pharmaceuticals, Inc. | $63.6B | $612.50 | $836.00 | +37.1% | Buy | 13.1x | 48 |
SMRTSmartRent, Inc. | $212M | $1.10 | $4.00 | +254.0% | Hold | — | 15 |
ULTAUlta Beauty, Inc. | $20.0B | $464.91 | $671.13 | +47.1% | Buy | 15.9x | 47 |
EYENational Vision Holdings, Inc. | $1.4B | $16.96 | $30.83 | +83.7% | Buy | 24.0x | 14 |
ELThe Estée Lauder Companies Inc. | $30.5B | $84.53 | $102.08 | +20.4% | Hold | 34.9x | 46 |
COTYCoty Inc. | $1.7B | $1.91 | $3.94 | +102.1% | Hold | 8.8x | 33 |
Quick answers to the most common questions about buying EWCZ stock.
Wall Street's consensus price target for EWCZ is $5.8, -0.3% from its current price of $5.82. The below-market target from 8 analysts suggests limited near-term appreciation.
EWCZ has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $5.8 implies -0.3% downside from current levels.
With a forward P/E of 8.4655x, EWCZ trades at a relatively low valuation. The consensus target of $5.8 implies -0.3% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $5.8 for EWCZ, while the most conservative target is $5.8. The consensus of $5.8 represents the median expectation. Our quantitative valuation model projects a bull case target of $9 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EWCZ is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EWCZ stock forecast based on 8 Wall Street analysts shows a consensus price target of $5.8, with estimates ranging from $5.8 (bear case) to $5.8 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $7, with bear/bull scenarios of $4/$9.
Our quantitative valuation model calculates EWCZ's fair value at $7 (base case), with a bear case of $4 and bull case of $9. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 39/100.
EWCZ trades at a forward P/E ratio of 8.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 29.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on EWCZ, with 1 Sell ratings and a price target of $5.8 (-0.3% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EWCZ analyst price targets range from $5.8 to $5.8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.8 consensus represents the middle ground. Our model's $4-$9 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.